Chinese Guideline on the Management of Polypoidal Choroidal Vasculopathy (2022)

医学 指南 黄斑变性 分级(工程) 光动力疗法 眼科 养生 垂直波分 内科学 病理 脉络膜新生血管 工程类 土木工程 有机化学 化学
作者
Youxin Chen,Yuqing Zhang,Changzheng Chen,Hong Dai,Suyan Li,Xiang Ma,Xiaodong Sun,Shibo Tang,Yusheng Wang,Wenbin Wei,Feng Wen,Gezhi Xu,Weihong Yu,Meixia Zhang,Zhao Mingwei,Yang Zhang,Qi Fang,Xun Xu,Xiaoxin Li
出处
期刊:Chinese Medical Sciences Journal [Elsevier BV]
卷期号:38 (2): 77-93 被引量:2
标识
DOI:10.24920/004213
摘要

Background In mainland China, patients with neovascular age-related macular degeneration (nAMD) have approximately an 40% prevalence of polypoidal choroidal vasculopathy (PCV). This disease leads to recurrent retinal pigment epithelium detachment (PED), extensive subretinal or vitreous hemorrhages, and severe vision loss. China has introduced various treatment modalities in the past years and gained comprehensive experience in treating PCV.Methods A total of 14 retinal specialists nationwide with expertise in PCV were empaneled to prioritize six questions and address their corresponding outcomes, regarding opinions on inactive PCV, choices of anti-vascular endothelial growth factor (anti-VEGF) monotherapy, photodynamic therapy (PDT) monotherapy or combined therapy, patients with persistent subretinal fluid (SRF) or intraretinal fluid (IRF) after loading dose anti-VEGF, and patients with massive subretinal hemorrhage. An evidence synthesis team conducted systematic reviews, which informed the recommendations that address these questions. This guideline used the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach to assess the certainty of evidence and grade the strengths of recommendations. Results The panel proposed the following six conditional recommendations regarding treatment choices. (1) For patients with inactive PCV, we suggest observation over treatment. (2) For treatment-na?ve PCV patients, we suggest either anti-VEGF monotherapy or combined anti-VEGF and PDT rather than PDT monotherapy. (3) For patients with PCV who plan to initiate combined anti-VEGF and PDT treatment, we suggest later/rescue PDT over initiate PDT. (4) For PCV patients who plan to initiate anti-VEGF monotherapy, we suggest the treat and extend (T&E) regimen rather than the pro re nata (PRN) regimen following three monthly loading doses. (5) For patients with persistent SRF or IRF on optical coherence tomography (OCT) after three monthly anti-VEGF treatments, we suggest proceeding with anti-VEGF treatment rather than observation. (6) For PCV patients with massive subretinal hemorrhage (equal to or more than four optic disc areas) involving the central macula, we suggest surgery (vitrectomy in combination with tissue-plasminogen activator (tPA) intraocular injection and gas tamponade) rather than anti-VEGF monotherapy. Conclusions Six evidence-based recommendations support optimal care for PCV patients' management.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大马猴完成签到,获得积分10
刚刚
1秒前
斯文败类的应助被优美的剑采纳,获得10
1秒前
学术虫完成签到,获得积分10
1秒前
星空发布了新的文献求助10
1秒前
2秒前
程佑贵发布了新的文献求助10
2秒前
微信研友发布了新的文献求助10
2秒前
2秒前
2秒前
赘婿的应助被yier采纳,获得10
2秒前
ZY完成签到,获得积分10
2秒前
2秒前
搞怪的碧空完成签到,获得积分10
3秒前
DOC_LIU完成签到,获得积分10
3秒前
桑丘发布了新的文献求助10
3秒前
CXWjh完成签到,获得积分20
3秒前
炙热的书竹完成签到,获得积分10
3秒前
在水一方的应助被美杨杨采纳,获得10
3秒前
4秒前
舒适的迎南完成签到,获得积分10
4秒前
STEAM发布了新的文献求助10
4秒前
4秒前
5秒前
Sherry完成签到,获得积分10
5秒前
zmm完成签到 ,获得积分10
5秒前
5秒前
小刘发布了新的文献求助10
6秒前
goodgay133完成签到,获得积分10
7秒前
Mark完成签到,获得积分10
7秒前
fu完成签到,获得积分10
8秒前
8秒前
万能图书馆的应助被111采纳,获得10
8秒前
9秒前
9秒前
nobody完成签到,获得积分10
9秒前
瑾瑜玉完成签到 ,获得积分10
9秒前
小鱼儿完成签到,获得积分10
9秒前
10秒前
惊雷Jww完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180488
求助须知:如何正确求助?哪些是违规求助? 9570485
关于积分的说明 21812623
捐赠科研通 7776592
什么是DOI,文献DOI怎么找? 3433286
关于科研通互助平台的介绍 2557522
邀请新用户注册赠送积分活动 2479162